Osteoporosis Drug May Fight Several Diseases
Study Shows Lasofoxifene Cuts Risk of Breast Cancer, Heart Attack, and Stroke
Do We Need Another Osteoporosis Drug?
In an editorial that accompanies the study, Caroline Becker, MD, of Brigham
and Women's Hospital in Boston, questions whether the benefits of lasofoxifene
shown in this PEARL (Postmenopausal Evaluation and Risk-Reduction with
Lasofoxifene) study are enough to merit entering an already crowded field of
According to PEARL study information submitted to the FDA, Becker says,
lasofoxifene did not reduce the risk of new, symptomatic vertebral fractures
after three years of treatment. Instead it only reduced the risk of vertebral
fractures as shown by radiological (X-ray) evidence at five years.
In contrast, another SERM, raloxifene (Evista), has been shown to
significantly reduce both new symptomatic vertebral fractures as well as those
shown by X-rays.
"On balance, lasofoxifene seems to offer little, if any, advantage over
raloxifene as an agent against osteoporosis," Becker writes. "Although the
cardiovascular benefits reported in the PEARL trial seem impressive, one would
need to treat 492 patients for one year to prevent a single major coronary
Also, because lasofoxifene has not been tested in women at high risk for
heart disease, its safety in this group is unknown, she says.
"Given the plethora of drugs currently available for osteoporosis, studies
of new agents should show clear benefits over existing agents," Becker writes.
"On the basis of this criterion, the results of the PEARL trial suggest that
lasofoxifene offers no major clinically important benefits over raloxifene for
the skeleton, breast, heart, or reproductive tract."